Status:
COMPLETED
Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Lead Sponsor:
Pfizer
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the effectiveness and safety, over 12 weeks, of 3 dosing regimens of CP-690,550 for the treatment of adults with moderate to severe chronic plaque psoriasis.
Eligibility Criteria
Inclusion
- Have been diagnosed with plaque psoriasis for at least 6 months.
- Have plaque psoriasis covering at least 15% of their total body.
- Be a candidate for phototherapy or systemic treatment of psoriasis (either naïve or history of previous treatment).
- Be willing and able to comply with scheduled visits, treatment plan and other study procedures.
Exclusion
- Currently have non-plaque forms of psoriasis or drug-induced psoriasis.
- Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot discontinue phototherapy.
- Subject is participating in another trial using an investigational agent or procedure.
- Women who are pregnant or breast-feeding or considering becoming pregnant.
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
197 Patients enrolled
Trial Details
Trial ID
NCT00678210
Start Date
July 1 2008
End Date
August 1 2009
Last Update
December 19 2012
Active Locations (44)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Tucson, Arizona, United States, 85710
2
Pfizer Investigational Site
Little Rock, Arkansas, United States, 72205
3
Pfizer Investigational Site
Oceanside, California, United States, 92056
4
Pfizer Investigational Site
Jacksonville, Florida, United States, 32204